Celtic Biotech

Executive Summary

Celtic Biotech is an Irish biotechnology company founded in 2018, focusing on novel therapeutics derived from snake venom neurotoxins, primarily crotoxin. Its lead candidate, CB-24, is designed to selectively induce programmed cell death in cancer cells while sparing healthy tissue, aiming to treat solid tumors and associated pain. The company is at a preclinical stage with no disclosed funding rounds or valuation. Its potential lies in the unique mechanism of action leveraging snake venom toxins, which have shown promise in oncology. However, the early-stage nature, lack of clinical data, and limited public information present significant risks. The company's success hinges on advancing CB-24 through preclinical studies and securing partnerships or funding for clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND submission for CB-2430% success
• Q3 2026Preclinical efficacy data release50% success
• TBDPartnership or licensing deal20% success